How a drug’s place on FDA’s shortage list changes the compounding rules
When FDA lists a drug as in shortage, some federal limits on compounding copies of that drug stop applying; when FDA resolves the shortage, they return. Here is how that works for 503A pharmacies and 503B outsourcing facilities.
The signal
A drug on FDA’s drug shortage list is not treated as commercially available for the section 503A copies limit, and outsourcing facilities may compound copies of an approved drug while it is on the list — flexibilities that end when FDA removes the drug from the list.
Why this matters
Shortage status can open and close the legal room for compounding. Pharmacies, outsourcing facilities and prescribers need to know where a drug stands on FDA’s list, and what happens to orders when a shortage ends.
NPHLA takeaway
Shortage-based flexibility is temporary by design. Build a documented check of FDA’s shortage database into compounding and purchasing decisions, and expect the ordinary limits to return when FDA resolves a shortage. General information, not legal advice.
Source file
- [1]
- [2]
- [3]
- [4]
- [5]
- [6]
Drafted with AI assistance from the sources listed in the Source File, then reviewed and approved by an NPHLA editor before publication. NPHLA links to sources and does not republish their text. Professional information only — not medical, legal or regulatory advice for any individual situation. Our standards.